Close menu




September 15th, 2021 | 12:17 CEST

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology
Photo credits: pixabay.com

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.

time to read: 3 minutes | Author: Nico Popp
ISIN: VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , SARTORIUS AG O.N. | DE0007165607

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Valneva: Here is what happens after the crash

    The Valneva share has caused a stir on the trading floor in recent weeks. The French Company is working on a classic inactivated vaccine against Sars-Cov2. This new vaccine could be an opportunity, especially given the remaining 25% or so of the German population who have been unable to get the shot. The assumption is that the willingness to vaccinate could increase with Valneva's vaccine. Many people are skeptical of mRNA technology, which is the basis for vaccines from BioNTech and Moderna. But the vaccine hopes surrounding Valneva have been dampened - the UK withdrew its order.

    While the approval process is expected to continue, the hopes of many shareholders have been dashed. As recently as last Friday, the share was trading around EUR 20 - and has crashed to around EUR 12.50 at present. As the order from the UK was the only major order, the situation for Valneva is serious. With such an order behind it, it is much easier to swiftly implement all the necessary investments as part of an approval process. Since analysts have also become more skeptical after the cancellation of the large order, investors should continue to be cautious about Valneva.

    Cardiol Therapeutics: Nasdaq investors are taking notice

    One company that has benefited from the Corona pandemic is Cardiol Therapeutics. The biotech Company addresses inflammatory heart disease and is in a Phase II trial with its compound CardiolRx. The Company recently received the green light from the US Food and Drug Administration (FDA). The main focus is on the safety of the active ingredient and also the positive effects on patients with acute myocarditis, i.e. inflammation of the heart muscle.

    The latter condition can occur in connection with Covid-19 but also as an extremely rare vaccination reaction. As a rule, such inflammations heal without consequences. However, patients with pre-existing conditions, obesity or permanent stress may suffer subsequent damage, and this is where Cardiol Therapeutics comes in. Cardiovascular diseases are one of the most frequent causes of death in Western countries. Cardiol's active ingredients can be regarded as safe and effective with a high degree of probability according to the current state of scientific knowledge, making the shares of Cardiol Therapeutics appear attractive. Since the stock is now listed on the Nasdaq and can attract the attention of the most important biotech investors there, speculative investors should take a closer look at the share. Currently, the value is correcting after a spectacular rise.

    Sartorius: Hidden Champion in several areas

    The Sartorius share has also experienced a spectacular rise, with the share climbing like clockwork for years. Sartorius makes disposables for drug manufacturing, laboratory instruments and other consumables. In 2020, sales of the relatively conservative Company rose a whopping 27.8%. However, since order intake grew even more dynamically simultaneously, investors need not be alarmed at all about the 2021 figures. Sartorius is benefiting from the pandemic but also from progress in the healthcare system in general. Since Sartorius is active not only in Europe (40% share of sales) but also in the Americas (approx. 34%) and Asia-Pacific (approx. 25%), the Goettingen-based Company is a true hidden champion. On top of that, there is a slim dividend.


    Although investors are unlikely to make any more big leaps with Sartorius shares, the stock could become attractive after a correction. Despite the correction, Valneva remains rather uninteresting - the withdrawal of its only customer is unsettling. On the other hand, everything is going according to plan at Cardiol Therapeutics. Here, a promising active ingredient finally seems to be getting the attention it deserves. The share is worth a look, especially during the correction.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on September 30th, 2025 | 07:40 CEST

    Antimony Resources, Rheinmetall, Novo Nordisk – Something is in the air!

    • Mining
    • antimony
    • Defense
    • Biotechnology

    Sufficient access to raw materials is crucial for any economy. The EU has compiled a list of 34 critical raw materials. How critical a raw material is classified depends on two parameters: "economic importance" and "supply risk." This list also includes a little-known but very important metalloid – antimony. The price of antimony skyrocketed at the end of 2024 in the wake of China's export ban. There are still exciting investment opportunities in this area.

    Read

    Commented by André Will-Laudien on September 30th, 2025 | 07:35 CEST

    High-tech super boom! 1,000% no problem—here is more from D-Wave, NetraMark and Palantir!

    • Biotechnology
    • AI
    • Digitization
    • hightech
    • computing
    • Software

    Artificial intelligence (AI) is currently revolutionizing drug development by analyzing enormous amounts of data in a very short time and making clinical trials much more targeted. Modern AI systems make it possible to select drug candidates with precision and predict the potential success of a therapy with a high degree of accuracy. Companies like NetraMark are already using these technologies profitably. Players such as D-Wave and Palantir are also among the pioneers of the new AI-driven economy and have seen their share prices rise by over 1,000%. Expectations for further growth are virtually limitless. The advent of quantum computer technology also marks the beginning of a new chapter in ultra-fast data processing. For forward-looking investors, this opens up attractive entry opportunities in dynamically expanding future markets. Those who bet on the right players early on can benefit from this change to an above-average extent.

    Read

    Commented by André Will-Laudien on September 29th, 2025 | 07:20 CEST

    Attention: Acquisitions! Biotechs like Evotec, PanGenomic Health, Pfizer, and BioNTech in focus

    • Biotechnology
    • Biotech
    • Healthcare
    • healthtech

    The biotech industry is in turmoil! With the expiration of blockbuster patents, there is a threat of sharp declines in revenue, which must be strategically compensated for. Driven by economic pressure and a growing focus on innovation and technology, the industry is increasingly turning to acquisitions of biotech companies with promising drug candidates, new technologies, and digital expertise. Not only are entire pipelines being acquired, but key players from the fastest-growing segments are also being targeted, particularly in the field of obesity therapies, where billions are being paid for drug candidates. Several examples illustrate this wave of transformation. Companies are restructuring, focusing their activities, and rapidly preparing for a phase of sustainable growth. The pace is picking up! Here are some promising investment ideas!

    Read